Decreasing BMI/weight immediately prior to starting anti-PD-1/PDL-1 monoclonal antibodies for treatment for stage IV non-small cell lung cancer is associated with shorter progression-free survival.

Revathi Kollipara,Ibtihaj Fughhi,Marta Batus,Sanjib Basu,Jeffrey A. Borgia,Philip Bonomi,Mary J. Fidler

Decreasing BMI/weight immediately prior to starting anti-PD-1/PDL-1 monoclonal antibodies for treatment for stage IV non-small cell lung cancer is associated with shorter progression-free survival.

2019

Revathi Kollipara
Ibtihaj Fughhi
Marta Batus
Sanjib Basu
Jeffrey A. Borgia
Philip Bonomi
Mary J. Fidler

e20710Background: Currently, prognostic markers associated with immunotherapy treatment outcomes in patients with metastatic NSCLC include PDL-1 expression, tumor mutational burden (TBM), and neutr...

Keywords:

Monoclonal antibody
Progression-free survival
Immunotherapy
Oncology
Stage IV non-small cell lung cancer
Pathology
Medicine
Internal medicine
anti pd 1
in patient
treatment outcome

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations